S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their
growth. It may also stop the growth of tumor cells by stopping blood flow to the tumor. This
phase II trial is studying how well sorafenib works in treating patients with recurrent or
metastatic head and neck cance